

Nasdaq: **BIAF**




bioAffinity Technologies, Inc.

Nasdaq: BIAF

Fiscal Year	Dec 31
Industry	Biotech
Recent Price ¹	\$3.19
Market Cap ¹	\$30.3M
Shares Out. ¹	9.5M
Float ¹	5.3M
Avg. Volume ¹ (90-day)	20,732
Revenue (ttm) ²	\$320k
Cash (mrq) ²	\$4.5M

¹ As of March 5, 2024 ² As of September 30, 2023

bioaffinitytech.com



Company Overview

bioAffinity Technologies addresses the urgent need for noninvasive, accurate earlystage cancer diagnosis and broad-spectrum cancer treatments. Lung cancer is the leading cause of cancer-related deaths. The Company's first product, CyPath® Lung, improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. CyPath® Lung, a laboratory developed test (LTD), is patient-friendly and physician focused. Physicians order CyPath® Lung for their patients after lung cancer screening reveals a suspicious finding.

Patients collect their sample at home and ship overnight in a pre-paid envelope to the Company's commercial laboratory, Precision Pathology Laboratory Services, where data is collected using flow cytometry. Proprietary automated data analysis, developed using artificial intelligence (AI), detects lung cancer by analyzing the lung microenvironment to identify cell populations that indicate malignancy. CyPath® Lung has shown high sensitivity (92%), high specificity (87%) and high accuracy (88%) in detecting early-stage lung cancer in patients with small pulmonary nodules less than 20 millimeters. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio.

Investment Highlights

Commercialization of CyPath® Lung test underway

- Pilot marketing and sales program launched for CyPath[®] Lung in Texas
- US Department of Defense purchased CyPath[®] Lung for an observational study and research into the test's use for screening
- AMA issued a CPT code for CyPath[®] Lung, paving the way for reimbursement by both private payors and public health insurance programs; CMS approved payment effective January 1, 2024
- 375% increase in tests ordered and processed in the three months ended February 29, 2024 compared to the prior three-month period

Lung cancer is the leading cause of cancer-related deaths worldwide

- Lung cancer is frequently detected in advanced stages, resulting in limited treatment options
- Global lung cancer diagnostics market forecast to reach \$4.7B by 2030
- Company holds strong international patent portfolio supporting worldwide commercialization

Company's newly acquired CAP/CLIA laboratory showed \$6.9 million revenues in 2022, with 12.5% growth in first half, 2023

- Company captures 100% of CyPath Lung revenues
- Precision Pathology Laboratory Services adds capacity for nationwide expansion under one structure
- Accretive in 2023; 100% return on cash investment expected in 24 months

Experienced leadership team

 Team includes CEO Maria Zannes (30+ years executive-level experience); Chief Science & Medical Officer Dr. Vivienne Rebel (20+ years of scientific research experience); and CFO Michael Dougherty (20+ years financial management/business strategy experience, including CFO of Amazon's Alexa division)

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip profiles, or other investor relations materials and presentations are usubject to change. RedChip Companies and its affiliates may buy and sell shares of securities or opinions of the issues mentioned on this website at any time. The information contained herein is not a render to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a notfler or solicitation or any offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity (including but not limited to lost profits), loss of opportunities, trading losses and damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits), loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market linvesting is inherently risky. RedChip Companies is not responsible for any gains or losser investor relations materials and present persons. The publicate electronically or in print. We strongly encourage all investors to conduct the opprince expressed on this website, the opprince or in other investor relations materials on the relations that it publiches electronically or in print. We strongly encluses and the opprince and encourage all investors to conduct the opprince and encourage all investors to conduct the desine of anot the relatis the

Nasdaq: **BIAF**






Value Proposition

bioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US Department of Defense's purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer diagnostics market is projected to reach \$4.7 billion by 2030. The Company's flow cytometry platform, enhanced by AI-driven automated data analysis, is being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach \$8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the Company with ownership at 39% and increasing. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis and treatment.

Recent & Anticipated Milestones



Leadership Team: Innovative, Experienced, Dedicated





executive in the medical, environmental and engineering fields; focused on building high performing corporate teams who meet ambitious business acals

& CEO

Michael Dougherty, MBA, CPA

Vice President & CFO 20+ years of experience in financial management and business strategy; previously CFO of Amazon's Alexa commercial domains, TINT, Filestack and Amazon Pay

Science & Medical Advisory Board



Sheila Habib, MD Director of Pulmonary Lung Nodule Clinic and the Luna Cancer Screening, South Texas VA



Neil Alexis, PhD Principal Investigator, UNC School of Medicine; Environmental Medicine, Asthma & Lung Biology



Gerard Silvestri MD, FCCP Professor of Medicine & Lung Cancer Pulmonology, Medical University of South Carolina



David Hill, MD Director, American Lung Association; Assistant Professor, Yale School of



Catherine Sears MD Assistant Professor. Indiana University School of Medicine

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not intended to meet the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not intended to meet the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not intended to meet the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information or varianty and is not an offer or solicitation of an offer or sylicitation or any direct, indirect, consequential, special or punitive damages that may arise out of the use or information provided to any person or entity (including but not timited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on



Vivienne Rebel, MD, PhD

EVP, Chief Science &

Medical Officer

cancer research; 11

vears at Harvard's

, Dana-Farber Cancer

Institute; received UT

Therapy and Research

Center's Discovery of

Health SA Cancer

the Year Award

Xavier Reveles Chief Operating Officer

25+ years experience creating, building and managing CAP/CLIA labs and creating and commercializing LDTs; clinical cytogeneticist, American Society of Clinical Pathology